Peripheral artery disease (PAD) is one of the most common cardiovascular complications in patients with type 2 diabetes mellitus (T2DM) and is a predictor of cardiovascular death. Interventions that reduce cardiovascular complications in this patient population are urgently required. In the EMPA-REG OUTCOME trial, the sodium glucose cotransporter 2 inhibitor empagliflozin reduced the risk of cardiovascular death by 38% (hazard ratio [HR], 0.62; 95% confidence interval [CI] 0.49–0.77) and hospitalization for heart failure (HHF) by 35% (HR, 0.65; 95% CI, 0.50–0.85) versus placebo when given in addition to standard of care. We report analyses of the effects of empagliflozin on cardiovascular outcomes, mortality, and renal outcomes in patients with and without PAD at baseline in the EMPA-REG OUTCOME trial.

Patients in EMPA-REG OUTCOME had T2DM (hemoglobin A1c, 7%–10%), established cardiovascular disease, and estimated glomerular filtration rate ≥30 mL·min⁻¹·1.73 m⁻² at baseline. PAD at inclusion was defined as the presence of any of the following: limb angioplasty, stenting, or bypass surgery; limb or foot amputation resulting from circulatory insufficiency; evidence of significant peripheral artery stenosis (>50% on angiography, or >50% or hemodynamically significant via noninvasive methods) in ≥1 limb; and ankle brachial index <0.9 in ≥1 ankle. Patients were randomized 1:1:1 to empagliflozin 10 mg, empagliflozin 25 mg, or placebo in addition to standard of care. Cardiovascular outcome events and deaths were prospectively adjudicated by Clinical Events committees. An independent ethics committee or institutional review board approved the clinical protocol at each participating center. Patients provided informed consent before study entry.

In subgroups by PAD at baseline (yes/no), we assessed the risk of cardiovascular death, 3-point major adverse cardiovascular events (MACE; cardiovascular death, nonfatal myocardial infarction, nonfatal stroke), 4-point MACE (3-point MACE plus hospitalization for unstable angina), all-cause mortality, HHF, the composite of HHF or cardiovascular death, and incident or worsening nephropathy (defined as progression to macroalbuminuria, doubling of serum creatinine, initiation of renal replacement therapy, or death caused by renal disease) with empagliflozin pooled versus placebo using a Cox proportional hazards model. The model included factors for age, sex, baseline body mass index, hemoglobin A1c, estimated glomerular filtration rate, region, treatment, PAD, and treatment-by-PAD interaction. P values for the treatment-by-subgroup interaction were obtained from tests of homogeneity of treatment group differences among subgroups with no adjustment for multiple testing. Kaplan-Meier estimates are presented for cardiovascular death. Lower limb amputation (LLA) was identified via a systematic search of serious adverse event (AE) narratives, from events reported as AEs, and from those reported as a medical procedure under concomitant therapy in electronic case report forms or in investigator comments describing AEs, and analyzed using a Cox proportional hazards model. Minor LLA was defined as any resection through or distal to the
articulation of the ankle. Minor LLA, major LLA, and other AEs were assessed descriptively.

Of 7020 patients treated, 1461 (20.8%) had PAD at baseline (982 treated with empagliflozin, 479 treated with placebo). In this group, baseline mean±SD age was 64.0±8.5 years, body mass index was 30.7±5.3 kg/m², hemoglobin A₁c was 8.12±0.86%, 69% were male, 10% had a history of HF, 67% were current or ex-smokers, 30% had estimated glomerular filtration rate <60 mL·min⁻¹·1.73 m⁻², 92% were on antihypertensive therapy, 75% were on lipid-lowering therapy, and 85% were on antiplatelet/anticoagulant therapy. In patients without PAD, the mean±SD age was 62.9±8.7 years, body mass index was 30.6±5.3 kg/m², hemoglobin A₁c was 8.06±0.84%, 72% were male, 10% had a history of HF, 57% were current or ex-smokers, 25% had estimated glomerular filtration rate <60 mL·min⁻¹·1.73 m⁻², 96% were on antihypertensive therapy, 83% were on lipid-lowering therapy, and 90% were on antiplatelet/anticoagulant therapy.

In patients with PAD at baseline, empagliflozin reduced cardiovascular death by 43% (HR, 0.57; 95% CI, 0.37–0.88), all-cause mortality by 38% (HR, 0.62; 95% CI, 0.44–0.88), 3-point MACE by 16% (HR, 0.84; 95% CI, 0.62–1.14), 4-point MACE by 7% (HR, 0.93; 95% CI, 0.70–1.24), HHF by 44% (HR, 0.56; 95% CI, 0.35–0.92), and incident or worsening nephropathy by 46% (HR, 0.54; 95% CI, 0.41–0.71) versus placebo, consistent with findings in patients without PAD (Figure, A). The reductions in cardiovascular death appeared early and persisted for the duration of the trial (Figure, B).

In summary, in the vulnerable subgroup of patients with T2DM and PAD, empagliflozin reduced mortality,
HHF, and progression of renal disease with no observed increase in the risk of LLA. The reduction in cardiovascular death with empagliflozin in patients with T2DM and PAD translates to a number needed to treat of 29 patients over 3.1 years to prevent 1 event. These data have important translational implications for risk reduction approaches in patients with T2DM and PAD.

ACKNOWLEDGMENTS
Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Elizabeth Ng and Wendy Morris of FleishmanHillard Fishburn, London, UK, during the preparation of this article. The authors were fully responsible for all content and editorial decisions, were involved at all stages of manuscript development, and have approved the final version.

SOURCES OF FUNDING
The EMPA-REG OUTCOME trial was funded by the Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance.

DISCLOSURES
Dr Verma has received research grants and/or speaking honoraria from BI/Lilly, AstraZeneca, Janssen, Merck, and Amgen. Dr Mazer has received consulting honoraria from Amgen, Boehringer Ingelheim, and Octapharma. Dr Al-Omran reports no disclosures. Dr Fitchett reports honoraria from Sanofi, Merck & Co, Amgen, AstraZeneca, Eli Lilly and Company, and Boehringer Ingelheim. Dr Inzucchi has consulted for Janssen, vTv Therapeutics, and Alere; served on Clinical Trial Steering/Executive committees for Boehringer Ingelheim, AstraZeneca, Novo Nordisk, Sanofi/Lexicon Pharmaceuticals, Daichi-Sankyo, and Eisai (TIMI [Thrombolysis in Myocardial Infarction]); and served on Data Monitoring Committees for Intarcia Therapeutics, Inc. Dr Zinman has received research grants awarded to his institution from Boehringer Ingelheim, AstraZeneca, and Novo Nordisk and honoraria from Janssen, Sanofi, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk, and Merck. U. Hehnke and Dr George are employees of Boehringer Ingelheim.

AFFILIATIONS
St. Michael’s Hospital, Division of Cardiac Surgery (S.V.), Department of Anesthesia (C.D.M.), Division of Vascular Surgery (M.A.-O.), and Division of Cardiology (D.F.), University of Toronto, Ontario, Canada. Department of Surgery, King Saud University, Riyadh, Saudi Arabia (M.A.-O.). Section of Endocrinology, Yale University School of Medicine, New Haven, CT (S.E.I.). Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany (U.H., J.T.G.). Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada (B.Z.). Division of Endocrinology, University of Toronto, Ontario, Canada (B.Z.).

FOOTNOTES
Circulation is available at http://circ.ahajournals.org.

REFERENCES